38 related articles for article (PubMed ID: 17908257)
1. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment.
Kernt M; Staehler M; Stief C; Kampik A; Neubauer AS
Acta Ophthalmol; 2008 Jun; 86(4):456-8. PubMed ID: 17908257
[TBL] [Abstract][Full Text] [Related]
2. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
3. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
4. Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography.
Tran TH; de Smet MD; Bodaghi B; Fardeau C; Cassoux N; Lehoang P
Br J Ophthalmol; 2008 Jul; 92(7):922-7. PubMed ID: 18577643
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
6. [Triamcinolone in the treatment of the diabetic macular edema--one-year results].
Dusová J; Studnicka J; Rencová E; Korda V; Hejcmanová D
Cesk Slov Oftalmol; 2008 Jul; 64(4):149-52. PubMed ID: 18780654
[TBL] [Abstract][Full Text] [Related]
7. Correlation of high-definition optical coherence tomography and fluorescein angiography imaging in neovascular macular degeneration.
Malamos P; Sacu S; Georgopoulos M; Kiss C; Pruente C; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4926-33. PubMed ID: 19494200
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration.
Theodossiadis PG; Liarakos VS; Sfikakis PP; Vergados IA; Theodossiadis GP
Am J Ophthalmol; 2009 May; 147(5):825-30, 830.e1. PubMed ID: 19211094
[TBL] [Abstract][Full Text] [Related]
9. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
10. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib.
Chung EJ; Yoo S; Lim HJ; Byeon SH; Lee JH; Koh HJ
Br J Ophthalmol; 2009 Jul; 93(7):958-63. PubMed ID: 19028740
[TBL] [Abstract][Full Text] [Related]
12. Effect of sorafenib on experimental choroidal neovascularization in the rat.
Park YH; Roh SY; Lee YC
Clin Exp Ophthalmol; 2010 Oct; 38(7):718-26. PubMed ID: 20497436
[TBL] [Abstract][Full Text] [Related]
13. [Clinical studies with sorafenib (Nexavar) in metastatic melanoma].
Hauschild A
J Dtsch Dermatol Ges; 2007 Apr; 5(4):345. PubMed ID: 17376105
[No Abstract] [Full Text] [Related]
14. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat.
Wang XQ; Fan JM; Liu YO; Zhao B; Jia ZR; Zhang Q
Int J Pharm; 2011 Oct; 419(1-2):339-46. PubMed ID: 21843612
[TBL] [Abstract][Full Text] [Related]
15. Retisert (Bausch & Lomb/Control Delivery Systems).
Lim LL; Smith JR; Rosenbaum JT
Curr Opin Investig Drugs; 2005 Nov; 6(11):1159-67. PubMed ID: 16312138
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Age-Related Macular Degeneration Therapies.
Fabre M; Mateo L; Lamaa D; Baillif S; Pagès G; Demange L; Ronco C; Benhida R
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014339
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development,
Luo Q; Yang J; Xu H; Shi J; Liang Z; Zhang R; Lu P; Pu G; Zhao N; Zhang J
Drug Deliv; 2022 Dec; 29(1):837-855. PubMed ID: 35277107
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib Repurposing for Ophthalmic Delivery by Lipid Nanoparticles: A Preliminary Study.
Bonaccorso A; Pepe V; Zappulla C; Cimino C; Pricoco A; Puglisi G; Giuliano F; Pignatello R; Carbone C
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834371
[TBL] [Abstract][Full Text] [Related]
19. Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye.
Santonocito M; Zappulla C; Viola S; La Rosa LR; Solfato E; Abbate I; Tarallo V; Apicella I; Platania CBM; Maugeri G; D'Agata V; Bucolo C; De Falco S; Mazzone MG; Giuliano F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922399
[TBL] [Abstract][Full Text] [Related]
20. Anthrax lethal toxin suppresses high glucose induced VEGF over secretion through a post-translational mechanism.
Zhang WW; Wang X; Xie P; Yuan ST; Liu QH
Int J Ophthalmol; 2015; 8(3):453-8. PubMed ID: 26085990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
